文献速递消化系统肿瘤

循环游离肿瘤DNA突变作为肝细胞癌生物标志物的鉴定

Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
PubMed 文献 · Eur J Cancer · 2019-06-04

研究纳入51例肝细胞癌患者和10例肝硬化患者,采用靶向多重PCR超深度测序检测血浆游离DNA及匹配肿瘤组织DNA中7个肝癌驱动基因突变。结果显示血浆游离DNA在所有样本中可检出,18/51例(35%)患者血浆中检出突变,与组织DNA匹配时特异性高但灵敏度低(71%组织突变未在血浆中检出)。

要点

  • 血浆游离DNA在所有肝细胞癌和肝硬化患者样本中均可定量检测。
  • 18/51例(35%)肝细胞癌患者血浆ctDNA中检出驱动基因突变,ARID1A最常见(11.7%)。
  • 血浆ctDNA与匹配肿瘤组织DNA突变检测特异性高但灵敏度低,71%组织突变未在血浆中检出。

核心结论

  • ctDNA在所有肝细胞癌分期中均可定量,并能检出肝细胞癌发生关键驱动基因的突变。
  • 本研究显示血浆ctDNA检测匹配肝细胞癌组织突变的特异性高但灵敏度低。

研究设计与样本

  • 从51例肝细胞癌患者和10例肝硬化患者中分离血浆游离DNA、匹配生殖系DNA和肝细胞癌组织DNA。
  • 采用肝癌特异性引物面板对ARID1A、ARID2、AXIN1、ATM、CTNNB1、HNF1A和TP53基因进行靶向多重聚合酶链反应超深度测序。
  • 分析血浆ctDNA与肝细胞癌组织DNA突变的一致性及其与临床结局的关联。

主要发现

  • 所有样本均检出�浆游离DNA。
  • 巴塞罗那临床肝癌分期A期患者血浆游离DNA中位浓度122.89 ng/mL,B/C/D期患者中位浓度168.21 ng/mL,A期较B/C/D期降低,p=0.041。
  • 18/51例患者(35%)在8个基因中检出29个突变(21个独特突变),每例患者中位1.5个突变(四分位距1-2)。
  • 突变最常见于ARID1A(11.7%),其次为CTNNB1(7.8%)和TP53(7.8%)。
  • 在具有匹配组织DNA的患者中,血浆ctDNA检出的所有突变均在肝细胞癌DNA中得到确认;但71%的患者在肝细胞癌组织DNA中检出的突变未在匹配ctDNA中检出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatocellular carcinoma (HCC) is increasing globally. Prognostic biomarkers are urgently needed to guide treatment and reduce mortality. Tumour-derived circulating cell-free DNA (ctDNA) is a novel, minimally invasive means of determining genetic alterations in cancer. We evaluate the accuracy of ctDNA as a biomarker in HCC. METHODS: Plasma cell-free DNA, matched germline DNA and HCC tissue DNA were isolated from patients with HCC (n = 51) and liver cirrhosis (n = 10). Targeted, multiplex polymerase chain reaction ultra-deep sequencing was performed using a liver cancer-specific primer panel for genes ARID1A, ARID2, AXIN1, ATM, CTNNB1, HNF1A and TP53. Concordance of mutations in plasma ctDNA and HCC tissue DNA was determined, and associations with clinical outcomes were analysed. RESULTS: Plasma cell-free DNA was detected in all samples. Lower plasma cell-free DNA levels were seen in Barcelona Clinic Liver Cancer (BCLC A compared with BCLC stage B/C/D (median concentration 122.89 ng/mL versus 168.21 ng/mL, p = 0.041). 29 mutations in the eight genes (21 unique mutations) were detected in 18/51 patients (35%), median 1.5 mutations per patient (interquartile range 1-2). Mutations were most frequently detected in ARID1A (11.7%), followed by CTNNB1 (7.8%) and TP53 (7.8%). In patients with matched tissue DNA, all mutations detected in plasma ctDNA detected were confirmed in HCC DNA; however, 71% of patients had mutations identified in HCC tissue DNA that were not detected in matched ctDNA. CONCLUSION: ctDNA is quantifiable across all HCC stages and allows detection of mutations in key driver genes of hepatic carcinogenesis. This study demonstrates high specificity but low sensitivity of plasma ctDNA for detecting mutations in matched HCC tissue.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Howell J, Atkinson SR, Pinato DJ, et al. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. Eur J Cancer. 2019. PMID: 31173963. doi:10.1016/j.ejca.2019.04.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。